Sex: F
Vaccine: RAB
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient was vaccinated with the first dose of RabAvert. Did not come back after one week but waited three weeks to return and was vaccinated with the second dose.; Case reference number US-BN-2023-001699 is a spontaneous case report initially received from a nurse via Med Communications (reference number: USBAV23-1767) on 23-Oct-2023 and concerns a female patient of unspecified age.   The patient's medical history and concomitant medication details were not provided.  On an unspecified date, the patient was vaccinated with *the first* dose of RabAvert (batch number: unknown) at an unknown dose, route, and site of administration, for pre-exposure immunization *for a trip*.  *On unspecified date, reported as after three weeks, the patient was vaccinated with the second dose of RabAvert (batch number: unknown) at an unknown dose, route, and site of administration*.  As reported, the patient did not come back after one week *for follow up appointment and waited for three weeks to return* (explicitly coded as 'inappropriate schedule of vaccine administered').  *As reported, the patient did not experience any adverse event due to RabAvert vaccine.*  Additional information received from Bavarian Nordic on 24-Oct-2023 included local BN case ID.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow up information received from a nurse on 08-Dec-2023: New information included confirmation that the patient did not experience any adverse event due to RabAvert vaccine, added RabAvert vaccination details for the second dose given after three weeks, indication updated, more details added to the narrative.; Reporter's Comments: A female patient of unspecified age was vaccinated with the second dose of RabAvert, at an unknown dose, route, and site of administration, however the patient did not come back after one week for follow up appointment but waited for three weeks to return which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is listed per company convention. At this point,  the patient did not experience any adverse event due to RabAvert vaccine. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of  product administration is not related to RabAvert, but to a human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age was vaccinated with the second dose of RabAvert, at an unknown dose, route, and site of administration, however the patient did not come back after one week for follow up appointment but waited for three weeks to return which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is listed per company convention. At this point,  the patient did not experience any adverse event due to RabAvert vaccine. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of  product administration is not related to RabAvert, but to a human factor. The case is non-serious.